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Abstract  20 
Two cases of suspected acute and lethal intoxication caused by propofol were delivered by 21 
the judicial authority to the Department of Sciences for Health Promotion and Mother-Child Care in 22 
Palermo, Sicily. In the first case a female nurse was found in a hotel room, where she lived with her 23 
mother; four 10 mg/mL vials and two 20 mg/mL vials of propofol were found near the decedent 24 
along with syringes and needles. In the second case a male nurse was found in the operating room 25 
of a hospital, along with a used syringe. In both cases a preliminary systematic and toxicological 26 
analysis (STA) indicated the presence of propofol in the blood and urine. As a result, a method for 27 
the quantitative determination of propofol in biological fluids was optimized and validated using a 28 
liquid-liquid extraction protocol followed by GC/MS and Fast GC/MS-TOF. In the first case, the 29 
concentration of propofol in blood was determined to be 8.1 g/mL while the concentration of 30 
propofol in the second case was calculated at 1.2 g/mL. Additionally, the tissue distribution of 31 
propofol was determined for both cases. Data emerging from the autopsy findings, histopathological 32 
exams as well as the toxicological results aided in establishing that the deaths were due to 33 
poisoning, however the manner of death in each were different: homicide in Case 1 and suicide in 34 
Case 2.   35 
 36 
 37 
 38 
 39 
 40 
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Introduction    43 
Propofol (2,6-diisopropylphenol), a sedative-hypnotic agent used for the induction of 44 
anesthesia and for sedating mechanically ventilated patients in intensive care units [1,2], is now 45 
increasingly being used for conscious sedation during endoscopic procedures. Propofol is an 46 
extremely rapid-acting intravenous anesthetic. Its advantages include less residual postoperative 47 
sedation and less psychomotor impairment compared to the barbiturates and less incidence of 48 
nausea and vomiting [3]. The blood concentration required for induction of anesthesia is generally 49 
2-10 g/L, while a concentration of 2-4 g/L is sufficient to maintain it [4,5]. Propofol produces 50 
dose-dependent cardiovascular and respiratory depression with a profile similar to methohexital. 51 
Side effects include pain on injection, involuntary muscle movements, coughing, and hiccoughing 52 
[6]. It has been associated with fatal heart failure both in children [7] and in adult patients with head 53 
injuries [8]. In fact, the constellation of myocardial failure, metabolic acidosis, and rhabdomyolysis 54 
in children receiving propofol infusions for more than 48 hours has been termed the propofol 55 
infusion syndrome  [9,10]. Propofol is known to induce hypertriglyceridemia, severe enough to 56 
cause pancreatitis, but only when used at a rate exceeding 100 μg kg–1min–1 for prolonged periods 57 
[11]. Propofol is also associated with abuse and dependency, especially among health care 58 
professionals [12-14], because of its rapid narcotic effect causing euphoria and sexual hallucinations 59 
[15]. 60 
Several fatal cases of poisoning have been reported [13-20]; in these cases a high variability 61 
in the blood concentration of propofol has been observed (from 0.08 to 8.7 g/L) [4].    62 
Two cases of suspected lethal intoxication caused by propofol were delivered by the judicial 63 
authority to the Department of Sciences for Health Promotion and Mother-Child Care in Palermo, 64 
Sicily in 2014. A GC/MS method previously developed and validated in our laboratory [21] was 65 
applied for the determination of volatile organic compounds (VOC) and the systematic 66 
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toxicological analysis (STA) on blood and urine collected from the two cases. In both cases STA 67 
indicated the presence of propofol in blood and urine. A method was therefore optimized and 68 
validated for the quantitative determination of propofol in the biological fluids using a liquid-liquid 69 
extraction protocol followed by GC/MS and Fast GC/MS-TOF. Blood, urine, bile and tissue 70 
concentrations were determined for both cases [22].  71 
 72 
Case history 73 
First case: female, nurse, 41 years old, sitting on a chair near a bed in a hotel room. Four 10 74 
mg/mL vials and two 20 mg/mL vials of propofol were found near the decedent together with 75 
syringes and needles. Signs of acupuncture on the left elbow, forearm, hand and foot were noted. 76 
Blood, urine, bile, brain and liver were obtained at the autopsy. 77 
Second case: male, nurse, 55 years old, found lying in an operating room with a syringe 78 
nearby. Sign of acupuncture on the right ankle. Blood, urine, brain, liver and kidney were obtained 79 
at the autopsy. 80 
 81 
Materials and methods 82 
 83 
Reagents, chemicals and standards 84 
All reagents were of analytical grade and were stored as indicated by the supplier. Ethyl 85 
acetate, 2-propanol, dichloromethane, methanol, ammonia, hydrochloric acid 37%, sodium chloride, 86 
sodium bicarbonate, sodium carbonate, anhydrous sodium sulfate sodium hydroxide, O,N-87 
bis(trimethylsilyl)trifluoroacetoamide-trimethylclorosilane (BSTFA-1% TMCS), pH 6 buffer were 88 
purchased from Sigma-Aldrich (St. Louis, MO, USA); Thymol and sodium sulfate were obtained 89 
from Farmalabor (Canosa di Puglia, Italy). MethElute Reagent 0.2 M in methanol (TMAH) was 90 
from Thermo Scientific (Waltham, MA, USA). Propofol was purchased from Archimica S.p.a 91 
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(Origgio, Italy).  Water (18.2 M·cm-1) was prepared by a Milli-Q System (Millipore, Darmstadt, 92 
Germany); other common chemicals were of the highest purity commercially available. 93 
Stock solutions of propofol (0.1, 0.25, 0.50, 1, 2, 3, 10, 20, 25, 50, 100 g/mL) and thymol 94 
(IS; 10, 100, 1000 g/mL) were prepared in methanol and stored at 4 °C.  95 
 96 
Systematic and toxicological analysis (STA) [21] 97 
 98 
Blood, urine and bile sample preparation 99 
 100 
Blood (1 mL), urine (1 mL) or bile (250 L) was added with IS (100 L, 10 g/mL), 101 
saline solution (up to 2 mL), bicarbonate-carbonate buffer (50 mg, 2/1 w/w, pH 9) and 102 
extracted with ethyl acetate (4 mL). The mixture was put on a rotary shaker (20 min, 15 rpm) 103 
and then centrifuged (5 min, 5000 rpm). The organic phase was separated, sodium sulfate was 104 
added and after centrifugation (5 min, 5000 rpm) the supernatant was withdrawn and the 105 
solvent evaporated. The residue was dissolved in ethyl acetate (100 L) before the analysis. 106 
To evaluate specificity blood, urine or bile working standard solutions were prepared as 107 
follows: 100 L of propofol standard solution (10 g/mL) were placed in vial and the solvent 108 
evaporated. Blank blood (1 mL), blank urine (1 mL) or blank bile (250 L), IS (100 L, 109 
10g/mL), saline solution (up to 2 mL), bicarbonate-carbonate buffer (50 mg, 2/1 w/w, pH 9) 110 
were added and the mixtures extracted as described before. 111 
 112 
Hydrolysis of propofol glucuronide and sulfate in urine and bile samples 113 
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 114 
The sample of urine (1 mL) or bile (250 L) was added with saline solution until a volume 115 
of 2 mL  and 1 mL of 6N hydrochloric acid was added. The mixture was heated at 105 °C for 1 h. 116 
After cooling, IS (100 L, 10 g/mL) was added, pH was adjusted to 8 and bicarbonate-117 
carbonate buffer (50 mg, 2/1 w/w, pH 9) was added. Then the mixtures were extracted as 118 
described before. 119 
Hydrolyzed urine or bile working standard solutions were prepared as follows: 100 L 120 
of propofol standard solution (10 g/mL) were placed in vial and the solvent evaporated. 121 
Blank urine (1 mL) or blank bile (250 L) and saline solution until a volume of 2 mL were 122 
added; the mixture was heated at 105 °C for 1 h. After cooling, IS (100 L, 10 g/mL) was 123 
added, pH was adjusted to 8 and bicarbonate-carbonate buffer (50 mg, 2/1 w/w, pH 9) was 124 
added. Then the mixtures were extracted as described before. 125 
 126 
Tissue sample preparation 127 
 128 
Each sample was homogenized with a blender or ball mill, depending on the quantity of 129 
material. The deproteinization of the biological matrix was performed by means of an ultrasonic 130 
bath: 100 mg of tissue (brain, liver or kidney) previously added with 4 mL of saline solution, 131 
bicarbonate-carbonate buffer (50 mg, 2/1 w/w, pH 9) and 100 µL of IS (10 g/mL) were 132 
sonicated for 15 minutes at room temperature. After 5 min centrifugation, a clear supernatant was 133 
separated and extracted with ethyl acetate (4 mL). The mixture was placed on a rotary shaker 134 
(20 min, 15 rpm) and then centrifuged (5 min, 5000 rpm). The organic phase was separated, 135 
anhydrous sodium sulfate was added and after centrifugation (5 min, 5000 rpm) the 136 
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supernatant was withdrawn and the solvent evaporated. The residue was dissolved in ethyl 137 
acetate (100 L) before the analysis. 138 
Tissue working standard samples were prepared as follows: 100 L of propofol 139 
standard solution (10 g/mL) were placed in vial and the solvent evaporated. Blank tissue (100 140 
mg), IS (100 L, 10 g/mL), saline solution (4 mL), bicarbonate-carbonate buffer (50 mg, 2/1 141 
w/w, pH 9) were added and the mixtures extracted as described before. 142 
 143 
GC/MS 144 
 145 
The analyses were performed on a HP6890 Series II GC system, with a split-splitless 146 
injection system and an MSD HP5973 MS detector (Agilent Technologies, Santa Clara, CA, USA) 147 
operated in electron ionization (EI) mode (70 eV). The GC was equipped with a Rxi®-5Sil MS (5% 148 
diphenyl/95% dimethyl polysiloxane, 30 m x 0.25 mm i.d., film thickness 0.25 m) capillary 149 
column (Restek, Bellefonte, PA, USA). 150 
GC/MS conditions: splitless; solvent delay, 3.5 min; injector temperature, 280°C; interface 151 
transfer line, 280°C; ion source, 280°C; oven temperature program, initial 70°C, 40°C/min up to 152 
110°C, then 15°C/min up to 300°C (3 min). Helium was used as the carrier gas at a flow rate of 1.2 153 
mL/min. The MS detector was operated in the scan mode, acquiring ions from m/z 50 to 550. The 154 
total analysis time was 21 min. 155 
 156 
GC/MS-TOF 157 
 158 
The analyses were performed on a Dani Master GC system, with a split-splitless injection 159 
system and a Dani Master TOF Plus detector (Dani Instruments, Cologno Monzese, Italy) operated 160 
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in electron ionization (EI) mode (70 eV). The GC was equipped with a Rxi
®
-5ms (Crossbond
®
,5% 161 
diphenyl/95% dimethyl polysiloxane, 10 m x 0.10 mm i.d., film thickness 0.15 m) capillary 162 
column (Restek, Bellefonte, PA, USA). 163 
The GC/MS conditions: split ratio 100:1; injector temperature, 250°C; interface transfer line, 164 
280°C; ion source, 200°C; oven temperature program, initial 70°C, 20°C/min up to 200°C, then 165 
30°C/min up to 300°C (17 s). Helium was used as the carrier gas at a flow rate of 0.5 mL/min. The 166 
MS detector was operated in the scan mode, acquiring ions from m/z 50 to 550. The total analysis 167 
time was 8 min. The selected ions were 163 and 178 for propofol and 135 and 150 for the IS. 168 
 169 
Method validation 170 
 171 
The specificity, accuracy, precision and linearity as well as the limit of detection (LOD) and limit of 172 
quantitation (LOQ) were evaluated using blood as matrix.  173 
The specificity was assessed by extracting control (blank) blood, urine, bile, brain, liver and kidney 174 
samples. The lack of interfering peaks at the same analyte retention times conferred acceptable selectivity. 175 
The linearity of the response of the GC/MS-TOF analysis was assessed for propofol by plotting 176 
drug/IS peak area ratios versus the total amount of drug in the standard solutions, with intervals of 25–2000 177 
total ng of analyte (25, 50, 75, 150, 200, 500, 1250, 1500, 2000 ngtot). The calibration curve (y = 0,0007x  178 
0,0204) gave good correlation coefficients (R
2
 > 0.9925) over the whole range. 179 
Accuracy was expressed as the per cent recovery (%REC) evaluated by analyzing, in triplicate, two 180 
standard propofol solutions (500 to 1250 ngtot). The averaged results were found to be satisfactory (mean 181 
%REC 86.6 at 500 and 111.1 at 1250 ngtot). 182 
Two standard solutions (500 to 1000 ngtot) were analyzed five times in the same day and over 5 days 183 
in order to evaluate the precision of the method. The intraday and interday %CV were respectively 7.55 and 184 
9.82% at 500 ngtot; 8.51 and 5.03% at 1000 ngtot. The obtained data demonstrated adequate reproducibility.  185 
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The LOD and LOQ were also evaluated and were found to be 10 and 25 ng evaluated as the 186 
concentration of the analyte which gives a signal to noise ratio of at least 3 and 10 respectively. 187 
 188 
Results and discussion 189 
 190 
STA was carried out on the biological samples of the two cases received. Blood and urine of both 191 
cases were evaluated; however bile was available only in the first case. Case 1 did not test positive for VOC; 192 
however Case 2 had a blood alcohol concentration of 0.2 g/L. Other non-volatile substances identified in the 193 
cases are reported in Table 1. As noted caffeine, cotinine and nicotine were identified in both cases and are 194 
considered toxicologically irrelevant. Of interest is the presence of a chromatographic peak whose mass 195 
spectrum correlated to silanized propofol (Fig. 1). Based on the nature of the two cases, the laboratory 196 
proceeded with developing an analytical method for the quantification of propofol in biological 197 
fluids and tissues.  198 
Due to the low recoveries obtained with the original SPE method [21], a liquid-liquid 199 
extraction protocol was developed with ethyl acetate at pH 9 (bicarbonate/carbonate buffer) to 200 
optimize the extraction of propofol in the organic phase. Thymol was chosen as internal standard. 201 
The extracts were silanized using O,N-bis(trimethylsilyl)trifluoroacetoamide-trimethylclorosilane 202 
(BSTFA-1% TMCS) as in the STA analysis, but due to the low reproducibility of the results by 203 
GC/MS, the determination of propofol after the liquid-liquid extraction protocol without 204 
derivatization was carried out. Unfortunately, two interfering species were detected: capric acid in 205 
blood and nicotine in urine samples (Fig. 2). 206 
At this point the chromatographic system was completely changed, using Fast GC/TOF, 207 
with narrower and shorter capillary columns. The fast heating and cooling rate of the GC oven and 208 
the fast acquisition rate of the MS detector, allow high sensitivity and resolution and the 209 
chromatographic separation results enhanced although the shortness of the column. In these 210 
conditions, the peak of propofol was completely separated from those of capric acid and nicotine 211 
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(Fig. 2). The method was validated using blood as matrix showing suitable selectivity, accuracy, 212 
precision, LOD, LOQ and linearity in the concentration ranges requested for propofol determination 213 
in biological specimen [5, 12-22].   214 
The optimized method was applied for the determination of propofol in the biological 215 
specimens from the two cases. Urine and bile samples were hydrolyzed because it is known that 216 
most of propofol is conjugated with glucuronic acid [5]. A chromatogram obtained for the analysis 217 
of blood of Case 1 is depicted in Figure 3. 218 
The results obtained analyzing the biological samples from the two cases are reported in 219 
Table 2.  220 
The interpretation of the results should be made with particular caution. It is still widely 221 
debated whether propofol can be used to suicidal overdose. Several coroners believe that it is not 222 
possible to commit suicide with propofol because the maximum voluntarily injectable quantity of 223 
propofol before losing consciousness is not sufficient to cause death [23]. Death could be caused by 224 
a continuous intravenous infusion of the drug, with multiple organs failure mimicking propofol-225 
related infusion syndrome. The two cases show very different propofol concentrations especially in 226 
blood and urine. In Case 2 propofol levels, found in blood and urine, were below the therapeutic 227 
range and in accordance with the literature [4-8]. Death was probably caused by the respiratory 228 
depression caused by propofol, assumed in uncontrolled conditions. The drug was probably 229 
assumed by an intravenous infusion. In fact the subject was a nurse and he was found in an 230 
operating room with a single sign of acupuncture in his arm. So suicidal hypothesis is the most 231 
likely.  232 
Case 1 was more complicated. The very high concentration of propofol found in blood 233 
seemed incompatible with a single voluntary injection of propofol [23]. In fact propofol causes very 234 
rapid loss of consciousness. Even an intravenous infusion can hardly be responsible for a so high 235 
concentration.  236 
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 Examining circumstantial data, the presence of several ampoules of “Propofol Kabi” in the 237 
room where the corpse was found, were evidenced. The corpse presented several signs of 238 
acupuncture. The police found out that the woman lived in the hotel room with her mother, also a 239 
nurse, in poor conditions; they gambled and had many debts. Probably they decided to both commit 240 
suicide, the mother injected some vials of propofol to the daughter but then changed her mind and 241 
did not kill herself. Death in the first case is then to be ascribed to an homicide rather than a suicide. 242 
In conclusion both deaths were related to propofol poisoning though with a different manner, 243 
homicide in Case 1 and suicide in Case 2. These considerations were deduced taking into account 244 
blood and urine concentrations of propofol. To confirm the poisoning caused by this drug, also the 245 
tissues available from the autopsy were analyzed. The presence of propofol was confirmed also in 246 
all the tissues considered.    247 
 248 
Conclusions 249 
 250 
A liquid.liquid extraction protocol and a GC/MS and a Fast GC/MS-TOF method for the 251 
confirmation of propofol in the biological fluids was optimized and validated. The concentration of 252 
propofol was determined in blood, urine, bile, brain, liver and kidney of two suspected cases of 253 
poisoning caused by propofol. Data emerging from autopsy findings, histopathological exams and 254 
the concentrations of propofol evidenced by chemical and toxicological analysis, on the basis of 255 
literature data [4-16], allowed us to establish that both deaths were due to poisoning caused by 256 
propofol. In the first case the concentration of propofol in blood resulted to be 8.1 g/mL while in 257 
the second one it was 1.2 g/mL. The very different concentrations between the two cases were 258 
interpreted in two different ways: in the first case two females, mother and daughter, both nurses, 259 
decided to commit suicide with propofol, stolen by the daughter in the hospital where she worked. 260 
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The mother injected propofol in the ankle of the daughter, but then changed her mind and did not 261 
kill herself. In the second case a nurse committed suicide with an intravenous infusion of propofol.  262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
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Figure legends 357 
Fig. 1 SCAN analysis of case 1 blood (a); Mass spectrum of propofol-TMS (b) 358 
Fig. 2 Chromatograms of blood of Case 1 in GC/MS (a) and GC/TOF (b) and urine in GC/MS (c) 359 
and GC/TOF (d). A=Propofol; B=capric acid; C=nicotine 360 
Fig. 3 Chromatogram for the determination of propofol in blood of Case 1. 361 
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Fig. 2 387 
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Fig. 3 403 
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Table 1 Results of STA (n.d.= not determined) 404 
 405 
Specimen Case 1 Case 2 
Blood 
Cotinine 
Caffeine 
Cotinine 
Caffeine 
Urine 
Nicotine 
Cotinine 
Caffeine 
Nicotine 
Caffeine 
Bile Nicotine 
Cotinine 
n.d.
 
 406 
 407 
 408 
 409 
Table 2 Results of the quantitative determination of propofol in the biological specimens from the 410 
two cases 411 
 412 
Specimen 
Case 1  
(g/mL or g/g) 
Case 2 
(g/mL or g/g) 
Blood 8.1 1.2 
Urine 0.21 0.0073 
Hydrolyzed urine 1276.6 18.3 
Bile 3.28  
Hydrolyzed bile 105.7  
Brain 31.1 4.7 
Liver 52.2 49.1 
Kidney  2.3 
 413 
 414 
